Gastric Cancer Peritoneal Metastases
Conditions
Brief summary
It is an open label, phase II study involved receiving albumin-bound paclitaxel plus S-1 combined with sintilimab and bevacizumab in patients with gastric cancer peritoneal metastasis.
Interventions
DRUGalbumin-bound paclitaxel (260 mg/m2, d1)
260 mg/m2, d1)
DRUGS-1
80 mg/m2, d1-14
DRUGsintilimab
200 mg, d1
DRUGbevacizumab
First two cycles : intraperitoneally 7.5 mg/m2 Maintenance period: intravenously 7.5 mg/m2
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* 18 to 75 years patients histologically or cytologically confirmed the presence of GC or gastroesophageal junction tumor with PM (HER2 negative). The ECOG performance status is 0-1 and the expected survival time is more than 3 months. Did not receive any therapy for GC within the last six months (chemotherapy, radiation therapy, or both).
Exclusion criteria
* Principal
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival rate | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival | 1 year |
| Ascites drainage-free survival | 1 year |
| Objective Response Rate | 1 year |
Countries
China
Outcome results
None listed